Citations (7)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Aniket Bankar & Vikas Gupta. (2020) Investigational non-JAK inhibitors for chronic phase myelofibrosis. Expert Opinion on Investigational Drugs 29:5, pages 461-474.
Read now
Read now
Articles from other publishers (6)
Xiaofeng Liu, Binyou Wang, Yuan Liu, Yang Yu, Ying Wan, Jianming Wu & Yiwei Wang. (2023) JAK2 inhibitors for the treatment of Philadelphia-negative myeloproliferative neoplasms: current status and future directions. Molecular Diversity.
Crossref
Crossref
Yi Zhang, Hu Zhou, Zhongxing Jiang, Dengshu Wu, Junling Zhuang, Wei Li, Qian Jiang, Xiuli Wang, Jinwen Huang, Huanling Zhu, Linhua Yang, Xin Du, Fei Li, Ruixiang Xia, Feng Zhang, Jianda Hu, Yan Li, Yu Hu, Jing Liu, Chenghao Jin, Kai Sun, Zeping Zhou, Liqing Wu, Wenjuan Yu & Jie Jin. (2022)
Safety and efficacy of jaktinib in the treatment of Janus kinase
inhibitor‐naïve
patients with myelofibrosis: Results of a phase
II
trial
. American Journal of Hematology 97:12, pages 1510-1519.
Crossref
Crossref
Dahniel Sastow, John Mascarenhas & Douglas Tremblay. (2022) Thrombocytopenia in Patients With Myelofibrosis: Pathogenesis, Prevalence, Prognostic Impact, and Treatment. Clinical Lymphoma Myeloma and Leukemia 22:7, pages e507-e520.
Crossref
Crossref
Johannes Wohlrab, David Stintzing, Luise Schultz, Konstantin Jügelt & Olaf H.-U. Schroeder. (2022) Influence of Janus Kinase Inhibitors on the Neuronal Activity as a Proof-of-Concept Model for Itch. Skin Pharmacology and Physiology 35:2, pages 94-101.
Crossref
Crossref
Cristian H. Campos, Tatiana M. Bustamante, Verónica A. Jiménez, Cecilia C. Torres & Joel B. Alderete. (2021) Efficient and recyclable gold nanoparticles as catalysts for the cleaner production of 4-morpholinoanilines used as pharmaceutical building blocks. Journal of Cleaner Production 290, pages 125761.
Crossref
Crossref
Jingrui Liu, Binhua Lv, Hewen Yin, Xiaoxue Zhu, Haijing Wei & Yanhua Ding. (2020) A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Ascending Dose and Food Effect Study to Evaluate the Tolerance, Pharmacokinetics of Jaktinib, a New Selective Janus Kinase Inhibitor in Healthy Chinese Volunteers. Frontiers in Pharmacology 11.
Crossref
Crossref